New Data on 2 Alzheimer’s Drugs Alters Hope and Expectation by ANDREW POLLACK

By ANDREW POLLACK

Solanezumab, from Eli Lilly, is getting another look for mild cases, and Biogen said data from a small group taking aducanumab showed mixed results.

Published: July 23, 2015 at 12:00AM

from NYT Business Day http://ift.tt/1g4nMHK

from WordPress http://ift.tt/1SBkwzl
via Hadi Aboukhater